OncoMed recent pullback a buying opportunity, says Piper Jaffray Piper Jaffray recommends using the recent pullback in shares of OncoMed following the FDA's partial clinical hold on vantictumab as a buying opportunity. Piper wants to own shares ahead of the company's data read-outs in the second half of 2014. It reiterates an Overweight rating on the stock with a $43 price target.
News For OMED From The Last 14 Days
Check below for free stories on OMED the last two weeks.